The DOI matches its Crossref record; 131 of the 132 references it cites were found in a registry or an index.
Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis
Abstract
The amyloid cascade hypothesis of Alzheimer's disease (AD) is testable: it implies that interference with Abeta aggregation and plaque formation may be therapeutically useful. Abeta42 immunisation of amyloid precursor protein (APP) transgenic mice prevented plaque formation and caused removal of existing plaques. The first clinical studies of Abeta immunisation in AD patients (AN1792, Elan Pharmaceuticals) were halted when some patients suffered side effects. Since our confirmation that Abeta immunisation can prompt plaque removal in human AD, we have performed a clinical and neuropathological follow up of AD patients in the initial Elan Abeta immunisation trial. In immunised AD patients, we found: a lower Abeta load, with evidence that plaques had been removed; a reduced tau load in neuronal processes, but not in cell bodies; and no evidence of a beneficial effect on synapses. There were pathological "side effects" including: increased microglial activation; increased cerebral amyloid angiopathy; and there is some evidence for increased soluble/oligomeric Abeta. A pathophysiological mechanism involving effects on the cerebral vasculature is proposed for the clinical side effects observed with some active and passive vaccine protocols. Our current knowledge of the effects of Abeta immunotherapy is based on functional information from the early clinical trials and a few post mortem cases. Several further clinical studies are underway using a variety of protocols and important clinical, imaging and neuropathological data will become available in the near future. The information obtained will be important in helping to understand the pathogenesis not only of AD but also of other neurodegenerative disorders associated with protein aggregation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is also evidence that amyloid removal is faster in those patients with high baseline levels, further confounding a direct comparison of anti-Aβ antibodies 90 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [90]
In the citing paper
“| Gantenerumab | 13 1 | 42 b /27 | 67 | 52 | 2.5 | 48 b | 19.2 |”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [90]
In the citing paper
“| Gantenerumab | 13 1 | 42 b /27 | 67 | 52 | 2.5 | 48 b | 19.2 |”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [90]
In the citing paper
“| Gantenerumab | 13 1 | 42 b /27 | 67 | 52 | 2.5 | 48 b | 19.2 |”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [90]
In the citing paper
“| Gantenerumab | 13 1 | 42 b /27 | 67 | 52 | 2.5 | 48 b | 19.2 |”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [90]
In the citing paper
“In one human study, a vaccine to Aβ did reduce plaque burden, a remarkable technical achievement [248, 249].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [248]
In the citing paper
“In the first active immunization trial, the AN-1792 vaccine seemed to show some ability to clear Aβ plaque-associated tau lesions through plaque removal179–181”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [180]
In the citing paper
“There are multiple reasons why these trials may have failed, including the late timing of the therapy. Thus, conclusions drawn from these trials may be premature (72, 73).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [72]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Research works printed but not linked: 1
- Oh JY, Nam YJ, Jo A et al (2010) Apolipoprotein (APOE) mRNA is transported to dendrites and may have a role in synaptic structural plasticity. J Neurochem [Epub ahead of print] 2010 April 28. doi: 10.1111/j.1471-4159.2010.06773 · DOI
Cited by
Sorted by citations
Items 101–136 of 136
A century of confusion in researching Alzheimer’s disease
Garrett, M. D., & Valle, R. (2016) · International Journal of Healthcare · doi:10.5430/ijh.v2n2p13 · Cited by 7
“[11–13] If the removal of the neuropathology does not reverse the disease, then Alzheimer’s disease must be an expression of as yet, an unknown disease.”
BackgroundPreclinical Alzheimer disease — the new frontier
Knopman, D. S. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.153 · Cited by 7
Zedde, M., Losa, M., Grisafi, E., Lucia, D. D., Gandoglia, I., Sette, M. D., Pardini, M., Roccatagliata, L., Pascarella, R., & Piazza, F. (2026) · Biomolecules · doi:10.3390/biom16010089 · Cited by 6
“In fact, recent studies examining CMBs found decreased or no A β as well as fibrinoid necrosis at the site of vessel rupture, causing vessel remodeling and signaling BBB leakage [71].”
A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta.
Guo, W., Sha, S., Jiang, T., Xing, X., & Cao, Y. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.27.010 · Cited by 7
“We also cannot exclude the possibility that in highly Aβ-immunogenic patients clearance of antibody-resistant plaques was facilitated by infiltrating T cells and macrophages [43-44] .”
BackgroundYu, Y., Li, Q., Wang, H., Liu, S., Pang, X., Xu, Q., Zhou, X., & Huang, P. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.05.005 · Cited by 6
Morgan, D., & Lamb, B. T. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13566 · Cited by 4
“40 In a more recent study, 23 to 24 months old PDAPP mice were treated for 3 months with a murine version of donanemab which lowered A β 42 levels by 40%–50% by ELISA but had no effect on histological A β deposition.”
BackgroundSilencing of Amyloid Precursor Protein Expression Using a New Engineered Delta Ribozyme
Aissa, M. B., April, M.-C., Bergeron, L. J., Perreault, J., & Lévesque, G. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/947147 · Cited by 5
“Second, lowering Aβ levels by increasing its clearance using a vaccine was successful in animal models [35, 36], but the results from human clinical studies indicated important side effects, and there were concerns about safety in humans [37].”
Could changing the course of Alzheimer’s disease pathology with immunotherapy prevent dementia?
Overk, C., & Masliah, E. (2019) · Brain · doi:10.1093/brain/awz165 · Cited by 4
“…after vaccination with AN1792 showed a consistent and striking removal of amyloid plaques primarily in the neocortex, with the clearance of fibrillar amyloid-b protein material primarily driven by microglia/macrophage-type cells (Masliah et al., 2005; Boche et al., 2010; Serrano-Pozo et al., 2010).”
BackgroundPeesapati, S., & Chakraborty, S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00261 · Cited by 2
Krick, K. E., Weekman, E. M., Johnson, S. N., Sudduth, T. L., Rogers, C. B., Nicolayson, E. J., Kleinhenz, M. T., & Wilcock, D. M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107013 · Cited by 3
Finn, Q., Pascual, B., Schulz, P. E., & Masdeu, J. C. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a9111 · Cited by 4
Harmine and its derivatives: A promising multi-target therapeutic avenue for Alzheimer’s disease
Shen, X., Dong, X., & Nao, J. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.03.006 · Cited by 3
Welikovitch, L. A., Oakley, D. H., Bennett, R. E., Serrano‐Pozo, A., Zhu, H., Ruiz‐Uribe, N. E., Zwang, T. J., Chibnik, L. B., Gómez‐Isla, T., Frosch, M. P., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03037-y · Cited by 4
Active immunization: A novel therapeutic strategy for treating Alzheimer's disease
Mazahir, F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178288 · Cited by 3
Lautenschlager, M. M., Lautenschlager, N. T., & Förstl, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_66 · Cited by 2
Schindowski, K., Schindowski, C., & Zimmermann, J. (2014) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s51786 · Cited by 2
“A reduced cognitive decline in immunized patients who responded with a high titer and reduction in post-mortem amyloid load has been reported.(21,22) However, amyloid load appears to not be correlated to cognition.”
Alzheimer’s disease vaccines: promises and pitfalls
Tabira, T. (2011) · Clinical Investigation · doi:10.4155/cli.11.71 · Cited by 2
Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer’s Disease
Kazim, S. F., & Iqbal, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00002-8 · Cited by 2
Why delay in effective treatment for Alzheimer's disease and related conditions
Iqbal, K., Liu, F., Gong, C., Dai, C., & Hu, W. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.08.002 · Cited by 1
Chimal‐Juárez, E., Jury, N., Gómez-Isaza, L., Troncoso, J. C., & Lasagna‐Reeves, C. A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71208 · Cited by 3
Role of Liver in Alzheimer’s Disease
(2020) · ARC Journal of Neuroscience · doi:10.20431/2456-057x.0403003 · Cited by 1
Role of Immunotherapy in Ameliorating Proteopathic Dementia
Singh, M., Pancham, P., Agarwal, S., Kaur, H., Agarwal, V., Tiwari, R. K., Mani, S., & Rachana, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_16 · Cited by 1
Singh, J., Sabbagh, M. N., Nair, A. K., Grundman, M., Kinney, G. G., Yuen, E., & Black, R. S. (2014) · Wiley eBooks · doi:10.1002/9781118730676.ch23 · Cited by 1
Lansbury, P. T. (2013) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-35491-5_10
“Finally, amyloid plaque load, as measured by PET imaging, does not correlate with symptom severity (Boche et al. 2010).”
BackgroundIMMUNOTHERAPY IN COMBINATION WITH BEHAVIORAL ENRICHMENT IN A CANINE MODEL OF AGING
Davis, P. R. (2014) · UKnowledge (University of Kentucky)
Active Immunization Against the Amyloid-β Peptide
Liu, E., & Ryan, J. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_2
Modern approach in the therapy of Alzheimer's disease
Rodin, D., Schwarzman, A. L., & Saranzeva, S. V. (2014) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2014-21-1-6-10
Isolation housing exacerbates Alzheimer’s Disease phenotype in aged APP KI micePreprint
Laroy, M., Saito, T., Saido, T., D’Hooge, R., & der Jeugd, A. V. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/777524
Harrison, C. H., Sakai, K., Johnston, D. A., Holmes, C., Boche, D., & Nicoll, J. A. R. (2022) · medRxiv · doi:10.1101/2022.12.08.22283144
Self-citationGenetic Polymorphisms of Apolipoprotein E and Their Impact on Ischemic Stroke Severity and Recovery
Yuan, H., Li, P., & Li, B. (2025) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.70025
Peesapati, S., & Chakraborty, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706545
The spectrum of cerebral amyloid angiopathy-related inflammation
Norton, E. J. (2026) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2026.03.002
A narrative review on preclinical/clinical trials on aducanumab
Goel, A., Garima, G., Jain, P., Bansal, S., Chopra, H., Gupta, S., Kumar, S., Dhanawat, M., & Aggarwal, N. (2026) · Scripta Medica · doi:10.5937/scriptamed57-59386
Zedde, M., Basso, G., Piazza, F., & Pascarella, R. (2026) · Springer eBooks · doi:10.1007/978-3-032-23618-0_7
Peesapati, S., & Chakraborty, S. (2026) · Soft Matter · doi:10.1039/d6sm00153j
Metadata
- Authors
- Boche, D., Denham, N., Holmes, C., & Nicoll, J. A. R.
- Affiliations
- Southampton General Hospital (GB)
- Corresponding author
- Boche, Delphine
- Venue
- Acta Neuropathologica
- Published
- 2010-07-15
- Volume
- 120
- Issue
- 3
- Pages
- 369-384
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2077023014
- Cited by
- 135
- References
- 132
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 1 · 2023: 3 · 2022: 8 · 2021: 1 · 2020: 8 · 2019: 12 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 5 · 2014: 15 · 2013: 19 · 2012: 15
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta immunotherapy, amyloid-beta 42, amyloid hypothesis, amyloid plaques, tau pathology, microglial activation, cerebral amyloid angiopathy, cerebral vasculature, vaccine side effects, amyloid precursor protein transgenic mice, Alzheimer's disease pathogenesis
- MeSH terms
- Alzheimer Disease, Animals, Brain, Clinical Trials as Topic, Humans, Peptide Fragments, Amyloid beta-Peptides, Immunotherapy, Active, Alzheimer Vaccines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
